Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab, Carboplatin, and Capecitabine for GEJ and Gastric Adenocarcinoma
NCT00780494Phase 2Completed
- Sponsor
- Stanford University
- Start
- Feb 2009
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Stanford University. Started Feb 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00780494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00780494.